Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Технические особенности циторедуктивных операций и внутрибрюшной гипертермической химиоперфузии

https://doi.org/10.24287/1726-1708-2020-19-4-224-233

Полный текст:

Аннотация

В последние годы интерес к циторедуктивным оперативным вмешательствам с внутрибрюшной гипертермической химиоперфузией (hyperthermic intraperitoneal chemotherapy, HIPEC) в детской онкохирургии растет. Во взрослой онкологии эти вмешательства зарекомендовали себя как «операция выбора» для определенных групп пациентов. Подходы к предоперационному обследованию и технические особенности выполнения подобных операций широко описаны для взрослых пациентов, тогда как для больных детского возраста таких работ нет, учитывая ограниченный мировой опыт выполнения циторедукции и HIPEC у детей. Настоящий обзор суммирует данные литературы о путях диссеминации опухолевого процесса, принципах его диагностики и выполнения перитонэктомии, исходя из локализации очагов диссеминации в различных анатомических областях брюшной полости у взрослых пациентов, а также демонстрирует анализ возможности использования этих подходов в педиатрической практике.

Об авторах

Д. Г. Ахаладзе
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия

Ахаладзе Дмитрий Гурамович, канд. мед. наук, руководитель группы торакоабдоминальной хирургии

117997, Москва, ул. Саморы Машела, 1



Г. С. Рабаев
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Н. С. Грачёв
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Список литературы

1. Kim S., Kim T.U., Lee J.W., Lee T.H., Lee S.H., Jeon T.Y. The perihepatic space: comprehensive anatomy and CT features of pathologic conditions. Radiographics 2007; 27 (1): 129–43 DOI: 10.1148/rg.271065050

2. Solass W., Struller F., Horvath P., Königsrainer A., Sipos B., Weinreich F. Morphology of the peritoneal cavity and pathophysiological consequences. Pleura Peritoneum 2016; 1 (4):193–201 DOI: 10.1515/pp-2016-0023

3. Han S.S., Sugarbaker P.H. Kocher maneuver to facilitate cytoreduction within the foramen of Winslow. J Surg Oncol 2017; 115 (7): 788–90. DOI: 10.1002/jso.24587

4. Dedrick R.L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 12: 1–6.

5. Cho H.K., Lush R.M., Bartlett D.L., Alexander H.R., Wu P.C., Libutti S.K., et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 1999; 39: 394–401. DOI: 10.1177/00912709922007967

6. Dedrick R.L., Myers C.E., Bungay P.M., DeVita V.T. Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1–11.

7. Lemoine L., Sugarbaker P., Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum. World J Gastroenterol 2016; 22 (34): 7692–707. DOI: 10.3748/wjg.v22.i34.7692

8. Sheth S., Horton K.M., Garland M.R., Fishman E.K. Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003; 23: 457–73; quiz 535–6. DOI: 10.1148/rg.232025081

9. Oliphant M., Berne A.S. Computed tomography of the subperitoneal space: demonstration of direct spread of intraabdominal disease. J Comput Assist Tomogr 1982; 6: 1127–37. DOI: 10.1097/00004728-198212000-00014

10. Levy A.D., Arnáiz J., Shaw J.C., Sobin L.H. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 2008; 28: 583–607; quiz 621–2. DOI: 10.1148/rg.282075175

11. Sugarbaker P.H. It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch 2000; 67: 5–8. DOI: 10.1272/jnms.67.5

12. Renzulli P., Lowy A., Maibach R., Egeli R.A., Metzger U., Laffer U.T. The influence of the surgeon’s and the hospital’s caseload on survival and local recurrence after colorectal cancer surgery. Surgery 2006; 139: 296–304. DOI: 10.1016/j.surg.2005.08.023

13. Karaosmanoglu D., Karcaaltincaba M., Oguz B., Akata D., Ozmen M., Akhan O. CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis. Eur J Radiol 2009; 71: 313–7. DOI: 10.1016/j.ejrad.2008.04.012

14. Sugarbaker P.H. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994; 219 (2): 109–11

15. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177 (3): 1053–64. DOI: 10.2353/ajpath.2010.100105

16. Le O. Patterns of peritoneal spread of tumor in the abdomen and pelvis. World J Radiol 2013; 5 (3): 106–12. DOI: 10.4329/wjr.v5.i3.106

17. Verwaal V.J., Kusamura S., Baratti D., Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 2008; 98: 220–3 DOI: 10.1002/jso.21060

18. Yan T.D., Morris D.L., Shigeki K., Dario B., Marcello D. Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Oncol 2008; 98: 224–7. DOI: 10.1002/jso.21069

19. Low R.N. Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. J Gastrointest Oncol 2016; 2: 58–71. DOI: 10.3978/j.issn.2078-6891.2015.11

20. Torkzad M.R., Casta N., Bergman A., Ahlström H., Påhlman L., Mahteme H. Comparison between MRI and CT in prediction of peritoneal carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist. J Surg Oncol 2015; 111 (6): 746–51. DOI: 10.1002/jso.23878

21. Mohkam K., Passot G., Cotte E., Bakrin N., Gilly F.N., Ledochowski S. Resectability of peritoneal carcinomatosis: learnings from a prospective cohort of 533 consecutive patients selected for cytoreductive surgery. Ann Surg Oncol 2016; 23: 1261–70. DOI: 10.1245/s10434-015-5005-2

22. Sugarbaker P.H., Sardi A., Brown G., Dromain C., Rousset P., Jelinek J.S. Concerning CT features used to select patients for treatment of peritoneal metastases, a pictorial essay. Int J Hyperth 2017; 33 (5): 497–504. DOI: 10.1080/02656736.2017.1317368

23. Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer; 1996. Рp. 359–74.

24. Goéré D., Souadka A., Faron M., Cloutier A.S., Viana B., Honoré C., et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 2015; 22 (9): 2958–64. DOI: 10.1245/s10434- 015-4387-5

25. Coccolini F., Catena F., Glehen O., Yonemura Y., Sugarbaker P.H., Piso P. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol 2015; 41 (7): 911–9. DOI: 10.1016/j.ejso.2015.03.231

26. Sugarbaker P.H. Cytoreductive surgery and perioperative chemotherapy: textbook and video atlas. Connecticut: CineMed Publishing; 2013

27. Villeneuve L., Thivolet A., Bakrin N., Mohamed F., Isaac S., Valette P.J., et al. BIG-RENAPE and RENAPE Working Groups. A new internet tool to report peritoneal malignancy extent. PeRitOneal Malignancy Stage Evaluation (PROMISE) application. Eur J Surg Oncol 2016; 42 (6): 877–82. DOI: 10.1016/j.ejso.2016.03.015

28. Sugarbaker P.H. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43: 15–25.

29. Glehen O., Mohamed F., Sugarbaker P.H. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240 (2): 278–85. DOI: 10.1097/01.sla.0000133183.15705.71

30. Dayal S., Taflampas P., Riss S., Chandrakumaran K., Cecil T.D., Mohamed F., Moran B.J. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 2013; 56 (12): 1366–72. DOI: 10.1097/DCR.0b013e3182a62b0d

31. Seshadri R.A., Hemanth R.E. Diagnostic laparoscopy in the preoperative assessment of patients undergoing cytoreductive surgery and HIPEC for peritoneal surface malignancies. Indian J Surg Oncol 2016; 7: 230. DOI: 0.1007/s13193-015-0486-9

32. Fagotti A., Ferrandina G., Fanfani F., Ercoli A., Lorusso D., Rossi M., et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006; 13: 1156–61. DOI: 10.1245/ASO.2006.08.021

33. Brun J.L., Rouzier R., Uzan S., Darai E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simpli ed score. Gynecol Oncol 2008 110: 354–9. DOI: 10.1016/j.ygyno.2008.04.042

34. Esquivel J., Averbach A., Chua T.C. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 2011; 253 (4): 764–8. DOI: 10.1097/SLA.0b013e31820784df

35. Esquivel J., Averbach A. Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin. Gastroenterol Res Pract 2012; 2012: 5. DOI: 10.1155/2012/981245

36. Passot G., Bakrin N., Isaac S., Decullier E., Gilly F.N., Glehen O., et al. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur J Surg Oncol 2014; 40 (8): 957–62. DOI: 10.1016/j.ejso.2013.10.002

37. Gallotta V., Fagotti A., Fanfani F., Ferrandina G., Nero С., Costantini B., et al. Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc 2014; 28 (6): 1808– 15. DOI: 10.1007/s00464-013-3390-9

38. Trinh H., Ott C., Fanning J. Feasibility of laparoscopic debulking with electrosurgical loop excision procedure and argon beam coagulator at recurrence in patients with previous laparotomy debulking. Am J Obstet Gynecol 2004; 190: 1394–7. DOI: 10.1016/j.ajog.2004.02.034

39. Nezhat F.R., Denoble S.M., Cho J.E., Brown D.N., Soto E., Chuang L., et al. Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers. JSLS 2012; 16 (4): 511–8. DOI: 10.4293/108680812X13462882736691

40. Magrina J.F., Cetta R.L., Chang Y.H., Guevara G., Magtibay P.M., et al. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy, and laparotomy. Gynecol Oncol 2013; 129: 336–40. DOI: 10.1016/j.ygyno.2013.01.015

41. Carmignani C.P., Sugarbaker T.A., Bromley C.M., Sugarbaker P.H. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003; 22: 465–72. DOI: 10.1016/j.ajog.2004.02.034

42. Sugarbaker P.H. The subpyloric space: an important surgical and radiologic feature in pseudomyxoma peritonei. Eur J Surg Oncol 2002; 28: 443–6. DOI: 10.1053/ejso.2001.1238

43. Sugarbaker P.H. Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Transl Gastrointest Cancer 2013; 2 (2): 54–74. DOI: 10.3978/j.issn.2224-4778.2013.01.02

44. Han S.S., Sugarbaker P.H. Kocher maneuver to facilitate cytoreduction within the foramen of Winslow. J Surg Oncol 2017; 115 (7): 788–90. DOI: 10.1002/jso.24587

45. Bijelic L., Sugarbaker P.H. Cytoreduction of the small bowel surfaces. J Surg Oncol 2008; 97: 176–9. DOI: 10.1002/jso.20912

46. Sugarbaker P.H. Avoiding diverting ileostomy in patients requiring complete pelvic peritonectomy. Ann Surg Oncol 2016; 23 (5): 1481–5. DOI: 10.1245/s10434-015-4961-x

47. Benhaim L., Honoré C., Goéré D., Delhorme J.B., Elias D. Huge pseudomyxoma peritonei: surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery. Eur J Surg Oncol 2016; 42 (4): 552–7. DOI: 10.1016/j.ejso.2016.01.015

48. Hertel H., Diebolder H., Herrmann J., Köhler C., Kühne-Heid R., Possover M., et al. Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol 2001; 83 (3): 481–4. DOI: 10.1006/gyno.2001.6338

49. Schwarz L., Votanopoulos K., Morris D., Yonemura Y., Deraco М., Piso P., et al. Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable?: Results of an international multicenter study. Ann Surg 2016; 263 (2): 369–75. DOI: 10.1097/SLA.0000000000001225

50. Mahdi H., Rose P.G., Gonzalez S., DeBernardo R., Knight J., Michener C., et al. Postoperative complications after distal pancreatectomy performed during cytoreductive surgery for gynecologic malignancies. Int J Gynecol Cancer 2015; 25 (6): 1128–33. DOI: 10.1097/IGC.0000000000000455

51. Chi D.S., Temkin S.M., Abu-Rustum N.R., Sabbatini P., Jarnagin W.R., Blumgart L.H. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. Gynecol Oncol 2002; 87 (1): 138– 42. DOI: 10.1006/gyno.2002.6717

52. Loizzi V., Rossi C., Cormio G., Cazzolla A., Altomare D., Selvaggi L. Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer 2005; 15 (1): 26–31. DOI: 10.1111/j.1048-891x.2005.14406.x

53. Darrad M., Harper S., Verghese A., Leveckis J., Pathak S. Synchronous and metachronous ureteric metastases from adenocarcinoma of the colon. Int J Clin Oncol 2012; 17 (2): 185–8. DOI: 10.1007/s10147-011-0274-7

54. Honore C., Souadka A., Goere D., Dumont F., Deschamps F., Elias D. HIPEC for peritoneal carcinomatosis: does an associated urologic procedure increase morbidity? Ann Surg Oncol 2012; 19 (1): 104–9. DOI: 10.1245/s10434-011-1820-2

55. Leapman M.S., Jibara G., Tabrizian P., Franssen B., Yang M.Y., Romanoff A., et al. Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study. Ann Surg Oncol 2014; 21 (4): 1153–8. DOI: 10.1245/s10434-013-3393-8

56. Smeenk R.M., Bex A., Verwaal V.J., Horenblas S., Zoetmulder F.A.N. Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol 2006; 93 (1): 20–3. DOI: 10.1002/jso.20427

57. Votanopoulos K.I., Randle R.W., Craven B., Swett K.R., Levine E.A., Shen P., et al. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 2014; 21 (3): 868–74. DOI: 10.1245/s10434-013-3354-2

58. Eveno C., Goéré D., Dartigues P., Honoré C., Dumont F., Tzanis D., et al. Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis. Ann Surg Oncol 2013; 20 (2): 491–6. DOI: 10.1245/s10434-012-2623-9

59. Sugarbaker P.H. Peritonectomy procedures. Surg Oncol Clin N Am 2003; 12 (3): 703–27. DOI: 10.1016/s1055-3207(03)00048-6

60. Konate A., Poupon J., Villa A., Garnier R., Hasni-Pichard H., Mezzaroba D., et al. Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J Surg Oncol 2011; 103: 6–9. DOI: 10.1002/jso.21740

61. Schenk K.E., Schierl R., Angele M., Burkhart-Reichl A., Glockzin G., Novotny A., et al. Cisplatin and oxaliplatin surface contamination in intensive care units (ICUs) and hospital wards during attendance of HIPEC patients. Int Arch Occup Environ Health 2016; 89 (6): 991–6. DOI: 10.1007/s00420-016-1137-3

62. Villa A.F., El Balkhi S., Aboura R., Sageot H., Hasni-Pichard H., Pocard M., et al. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health 2015; 53: 28–37. DOI: 10.2486/indhealth.2014-0025

63. Capron A., Destree J., Jacobs P., Wallemacq P. Permeability of gloves to selected chemotherapeutic agents after treatment with alcohol or isopropyl alcohol. Am J Health Syst Pharm 2012; 69: 1665–70. DOI: 10.2146/ajhp110733

64. Boutros C., Somasundar P., Espat N.J. Early results on the use of biomaterials as adjuvant to abdominal wall closure following cytoreduction and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2010; 8: 72. DOI: 10.1186/1477-7819-8-72

65. Glehen O., Osinsky D., Cotte E., Kwiatkowski F., Freyer G., Isaac S., et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10: 863–9. DOI: 10.1245/aso.2003.01.018

66. Kusamura S., Younan R., Baratti D., Costanzo P., Favaro M., Gavazzi C., et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106: 1144–5. DOI: 10.1002/cncr.21708

67. Ortega-Deballon P., Facy O., Jambet S., Magnin G., Cotte E., Beltramo J.L., et al. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 2010; 17: 1957–63. DOI:10.1245/s10434-010-0937-z

68. Facy O., Combier C., Poussier M., Magnin G., Ladoire S., Ghiringhelli F., et al. High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery 2015; 157: 72–8. DOI: 10.1016/j.surg.2014.06.006

69. Halkia E., Tsochrinis A., Vassiliadou D.T., Pavlakou A., Vaxevanidou A., Datsis A., et al. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 2015; 2015: 6. DOI:10.1155/2015/610597

70. Hayes-Jordan A.A., Coakley B.A., Green H.L., Xiao L.C., Fournier K.F., Herzog C.E., et al. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial. Ann Surg Oncol 2018; 25 (4): 872–7. DOI: 10.1245/s10434-018-6333-9

71. Scalabre A., Philippe-Chomette P., Passot G, Orbach D., Elias D., Corradini N., et al. Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years. Pediatr Blood Cancer 2018; 65 (4): e26934. DOI: 10.1002/pbc.26934


Для цитирования:


Ахаладзе Д.Г., Рабаев Г.С., Грачёв Н.С. Технические особенности циторедуктивных операций и внутрибрюшной гипертермической химиоперфузии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(4):224-233. https://doi.org/10.24287/1726-1708-2020-19-4-224-233

For citation:


Akhaladze D.G., Rabaev G.S., Grachev N.S. Technical features cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Pediatric Hematology/Oncology and Immunopathology. 2020;19(4):224-233. (In Russ.) https://doi.org/10.24287/1726-1708-2020-19-4-224-233

Просмотров: 179


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)